Results 291 to 300 of about 768,450 (337)

Microvascular Health as a Key Determinant of Organismal Aging

Advanced Science, EarlyView.
This review spotlights the emerging field of vascular aging, providing a comprehensive and critical overview of the molecular processes and clinical manifestations of vascular dysfunction during aging. By combining basic angioscience concepts with a critical analysis of innovative pre‐clinical aging models and lifestyle interventions, it offers a ...
Mattia Cenciarini, Andrea Uccelli, Francesca Mangili, Myriam Grunewald, Simone Bersini   +4 more
wiley   +1 more source

Helicobacter pylori as a Cause of Dyspepsia in Patients With End-Stage Renal Disease. [PDF]

Cureus
Bhatti S, German S, Aslam M, Ahmed I, Hyder A, Tareen K, Ismail H, Khan RTY, Hassan Luck N.   +8 more
europepmc   +1 more source

Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease

, 2015
Petar Dejanov, Beti Dejanova
openalex   +2 more sources

Treatment with Minicircle DNA Expressing a FGF23 Fragment in a Clinically relevant Mouse Model of X‐Linked Hypophosphatemic Rickets

Advanced Science, EarlyView.
The pathogenic role of PHEX isn't fully determined, and there is no radical cure for X‐linked hypophosphatemic rickets (XLHR). This study makes the first attempt to perform gene therapy using a minicircle DNA (MC‐DNA) vector expressing a fragment of FGF23 (amino acids 180‐251) in Phex‐T1349C mice and suggests MC‐DNA as a promisingly safe and effective ...
Huixiao Wu, Wanyi Zhao, Xinyu Chen, Yanzhou Wang, Shuoshuo Wei, Bo Xiang, Yingzhou Shi, Zongyue Li, Yangyang Yao, Jin Xie, Renyuan Qiu, Meng Shu, Shuo Xu, Ping Chen, Zhiying Chen, Yingjie Wu, Weibo Xia, Ling Gao, Yongfeng Song, Jiajun Zhao, Chao Xu   +20 more
wiley   +1 more source

Purple Urine Bag Syndrome in End-Stage Renal Disease: Recognizing the Unexpected. [PDF]

Cureus
Shirsat P, Sonavane K, Agarwal B, Agrawal G, Ponnam HC, Sakamuri L.   +5 more
europepmc   +1 more source

Enhancer Reprogramming Reveals the Tumorigenic Role of PTPRZ1 in Lung Squamous Cell Carcinoma

Advanced Science, EarlyView.
Lung squamous cell cancer (LUSC) is deadly due to lack of good treatments. Here, multiomics techniques are applied to LUSC tumors and find thousands of cancer‐specific enhancers controlling key genes. Interestingly, the gene PTPRZ1 is identified as a critical oncogene driven by the LUSC‐acquired enhancers. PTPRZ1 is activated by MDK, fueling cancer via
Yong‐Qiang Ning, Jie Wang, Yihui Zhang, Hongrui Li, Zenan Jiang, Xinyu Su, Xiao Yang, Xiaoxuan Wu, Bing Wei, Jianmin Ying, Jian Yan, Wenbin Li   +11 more
wiley   +1 more source

Economic burden of end stage renal disease: a case study in southern Iran. [PDF]

Health Econ Rev
Omranikhoo H, Shabani S, Esfandiari A, Salari H, Rezaee M.   +4 more
europepmc   +1 more source

Nonalcoholic Fatty Liver Disease Exacerbates the Advancement of Renal Fibrosis by Modulating Renal CCR2+PIRB+ Macrophages Through the ANGPTL8/PIRB/ALOX5AP Axis

Advanced Science, EarlyView.
The ANGPTL8/PIRB/ALOX5AP axis mediates liver‐kidney crosstalk. Hepatocytes secrete ANGPTL8, which binds to CCR2+PIRB+ macrophages in the kidneys, affecting the expression of ALOX5AP and enhancing the activation of these macrophages. Activated cells produce TGF‐β, IL‐6, and IL‐23, driving Th17 activation and promote the formation of myofibroblasts ...
Shuqi Wei, Diwen Shou, Siyuan Huang, Yingsi Wang, Quanzhen Liu, Jinfa Liu, Xiaoyu Lv, Yuyi Zeng, Liting Wei, Han Lin, Jiechuan Chen, Yangxiao Chen, Haoyu Zhong, Yanqing Zhou, Wen Ma, Li Wang, Guojun Qian, Jing Guo, Donglin Sun   +18 more
wiley   +1 more source

Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA)

, 2006
Keiko Chujo, Kenji Shima, Hiroaki Tada, Teruyo Oohashi, Jun Minakuchi, Syu Kawashima   +5 more
openalex   +2 more sources

Intravenous iRGD‐Guided, RBC‐Membrane Camouflaged Lactococcus Lactis Remodels Cold NSCLC and Enhances PD‐1 Blockade

Advanced Science, EarlyView.
This study presents an engineered probiotic platform, iRGD‐mRBC@FOLactis, combining red blood cell membrane cloaking and tumor‐penetrating peptide iRGD for enhanced PD‐1 blockade. The platform improves tumor targeting, immune cell activation and therapeutic efficacy in lung cancer, demonstrating significant promise in overcoming PD‐1/PD‐L1 therapy ...
Chen Chen, Junmeng Zhu, Xiao Liu, Jie Shao, Aoxing Chen, Yi Mei, Xinyin Zhang, Qinyi Chen, Lin Li, Baorui Liu   +9 more
wiley   +1 more source